CD274 and non-small cell lung carcinoma: One study (32) investigated the efficacy of immunotherapy in NSCLC patients grouped according to TMB and PD-L1 expression; it found that patients with higher TMB and PD-L1 ≥50% had an ORR of up to 57% with anti-PD-1/PD-L1 ICIs, so the inclusion of TMB and PD-L1 expression in multivariate prediction models should yield great predictive power.